Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

WorldHeart VAD study begins: Pivotal study of the Levacor ventricular assist device as a bridge to cardiac transplantation is under way, with the first successful implant occurring Jan. 13, according to WorldHeart. FDA granted conditional approval to begin the trial, which is ultimately expected to include 160 patients and 10 clinical sites, last August (1"The Gray Sheet" Aug. 24, 2009). Levacor is a bearingless, fully magnetically levitated, implantable centrifugal pump. Thoratec's HeartMate II and HeartMate XVE are the only left ventricular assist devices currently approved for bridge-to-transplant therapy. Thoratec announced last week it had received FDA approval for HeartMate II as a destination therapy, as well
Advertisement

Related Content

Financings In Brief
Financings In Brief
People In Brief
People In Brief
New Products In Brief
WorldHeart plans VAD study at 10 U.S. centers

Topics

Advertisement
UsernamePublicRestriction

Register

MT028417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel